Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer

 Appointment reflects growing strength and diversity of Cardurion’s pipeline

July 08, 2020 08:00 AM Eastern Daylight Time

BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Chris Morabito, M.D., as chief medical officer (CMO). Dr. Morabito joins Cardurion from Takeda Pharmaceuticals, where he most recently served as senior vice president and head, research and development (R&D), plasma-derived therapies, and where he previously served as vice president and global program leader, specialty cardiovascular (CV) disease.

“Cardurion has the opportunity to deliver life-changing therapies against previously un-drugged targets in heart failure and other cardiovascular diseases. I am delighted to be partnering with our experienced leadership team and look forward to helping the company bring transformative new medicines to patients.”

“We are thrilled that Chris is bringing to Cardurion his strong industry and operational leadership at a time when our lead program in heart failure is advancing in the clinic and our pipeline is maturing,” said Peter Lawrence, chief executive officer of Cardurion. “Chris has a deep background in cardiovascular drug development from his time at Takeda, Sanofi and Merck, as well as broad experience and skills in leading large groups and an array of mission critical projects. His vision and leadership will be essential to our ongoing work to bring transformative therapies to people with cardiovascular diseases.”

As head, R&D, plasma-derived therapies at Takeda, Dr. Morabito established a complete R&D organization and built a pipeline of life-transforming medicines for patients with rare and difficult-to-manage diseases. Prior to that, he served as head, pipeline strategy for global R&D at Takeda, where he influenced the integrated development of R&D programs across Takeda’s therapeutic areas. While in this role, Dr. Morabito was instrumental in the acquisition and integration of Shire that occurred in 2019. Dr. Morabito has extensive experience in cardiovascular disease drug development. He has led numerous programs in heart failure, pulmonary hypertension, atrial fibrillation, hypertension and diabetes mellitus at Merck, Sanofi and Takeda. He has overseen numerous Phase 1, proof-of-concept and pivotal studies, including CV outcome studies. Dr. Morabito trained initially as a neonatologist at the Cardiovascular Research Institute at University of California, San Francisco, where he focused on neonatal cardiology and was an NIH-funded scientist interrogating mechanisms of cardiomyocyte development.

“I am excited to join Cardurion at this important time, when both our lead program and broader pipeline are entering important phases in the development cycle,” said Dr. Morabito. “Cardurion has the opportunity to deliver life-changing therapies against previously un-drugged targets in heart failure and other cardiovascular diseases. I am delighted to be partnering with our experienced leadership team and look forward to helping the company bring transformative new medicines to patients.”

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Built by a team of physician-scientists and industry experts with extensive experience in cardiovascular science, medicine and drug development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs to target major unmet needs in cardiology. Cardurion Pharmaceuticals has facilities in Boston, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com

 

Contacts
Gwen Schanker
Ten Bridge Communications
gwen@tenbridgecommunications.com
269-921-3607

Read More

Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer

April 15, 2020 07:30 AM Eastern Daylight Time

BOSTON – (BUSINESS WIRE Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Peter S. Lawrence as president and chief executive officer. Mr. Lawrence joins Cardurion after serving for almost 14 years as president and chief operating officer of ArQule, Inc., which was successfully sold to Merck in January 2020 for $2.7 billion. Mr. Lawrence succeeds Michael E. Mendelsohn, M.D., founder and interim CEO of Cardurion, who will continue in his role as chairman of Cardurion’s Board of Directors.

“Pete’s demonstrated success as a skilled and experienced biotechnology leader will be a tremendous asset to Cardurion as we progress our preclinical and clinical-stage pipeline of cardiovascular drug candidates into later-stage clinical development and ultimately to market,” said Dr. Mendelsohn. “His leadership will be critical to guiding Cardurion as we realize our long-term vision to bring life-changing new therapies to patients with heart disease.”

Mr. Lawrence brings more than 20 years of experience as a life sciences executive and investor with a track record of company building, deal making and operational leadership. In addition to his strategic role as president of ArQule, Mr. Lawrence oversaw the company’s R&D and manufacturing operations as well as its corporate and business development, new product planning, IT, legal and IP functions. Concurrently, he served as principal financial officer for ArQule and in that role helped raise over $350 million through six public financings. Additionally, Mr. Lawrence facilitated collaborations with ArQule’s pharmaceutical and biotechnology partners, overseeing partnerships with a total value in excess of $1 billion and providing the company hundreds of millions of dollars in milestone payments and development support. Before joining ArQule, Mr. Lawrence was a founder and general partner of Pod Venture Partners and previously was a corporate law equity partner at Mintz Levin. He holds a degree in history and Russian studies from Amherst College and a J.D. from Boston University School of Law.

“The Cardurion team is applying its deep cardiovascular expertise, strong drug discovery and clinical development backgrounds and an extensive industry and academic network to acquire and discover novel drug candidates to address cardiovascular disease,” said Mr. Lawrence. “I am excited about the opportunity to lead this talented team as we progress our most advanced clinical program into later-stage clinical testing in both forms of heart failure, while also bringing forward our preclinical pipeline of novel cardiovascular medicines.”

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Built by a team of physician-scientists and industry experts with extensive experience in cardiovascular science, medicine and drug development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs to target major unmet needs in cardiology. Cardurion Pharmaceuticals has facilities in Boston, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

 

Media Contact
Gwen Schanker
Ten Bridge Communications
gwen@tenbridgecommunications.com
269-921-3607

Read More

Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors

BOSTON, Mass. – November 20, 2019 – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced that it has consummated a private investment from Polaris Partners, a leading healthcare investment firm with a long history of partnering with entrepreneurs in biotechnology. Polaris Partners joins existing investor Takeda Pharmaceuticals. As part of the investment, Amy W. Schulman, a managing partner at Polaris Partners, will join the Cardurion Board of Directors.

“We are honored to have Polaris Partners, with its long history of leadership in biotechnology investing and company building, partner with us as we pursue novel drugs to treat cardiovascular diseases, and we are especially pleased to have Amy Schulman of Polaris bring her deep strategic and leadership experience to our board,” said Dr. Michael E. Mendelsohn, founder and chairman of Cardurion Pharmaceuticals. “Cardurion is dedicated to advancing novel mechanisms to create new treatments for cardiovascular diseases, which remain the greatest cause of morbidity and mortality in our society. Our lead clinical program studying CRD-733, a novel phosphodiesterase-9 enzyme (PDE9) inhibitor, is in development for the treatment of heart failure, which remains a major cause of death in our society. Our two discovery programs focus on unique molecular targets for other cardiovascular diseases, including both rare and more common arrhythmia disorders.”

Amy W. Schulman, a managing partner at Polaris Partners who will be joining Cardurion’s board, noted that cardiovascular disease affects millions of people in the United States alone. “This area of clear critical need, coupled with Michael’s deep expertise in the field, were important factors in Polaris’ decision to invest. Cardurion’s robust pipeline programs, led by a PDE9 inhibitor already in the clinic for the treatment of both forms of heart failure, are also factors underscoring Polaris’ enthusiasm for this platform.”

The securities issued have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful.

 

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Founded by physician-scientist Michael E. Mendelsohn, M.D., with extensive experience in cardiovascular science, medicine and drug development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs targeting major unmet needs in cardiovascular medicine. Cardurion Pharmaceuticals has facilities in Boston, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

 

About Polaris Partners

Polaris Partners has a 20-plus year history of partnering with repeat entrepreneurs and world-class innovators who are improving the way we live and work. The multibillion-dollar firm manages specialty and diversified funds in healthcare and technology with investments across all stages. Polaris has offices in Boston and San Francisco. Learn more at polarispartners.com.

Investor and Media Contact

Michael E. Mendelsohn, M.D.

Cardurion Pharmaceuticals

info@cardurion.com

617-863-8088

Read More

Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure
CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models

November 12, 2018 09:00 AM Eastern Standard Time

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced preclinical results from its study of CRD-733, the company’s novel Phosphodiesterase-9 enzyme (PDE-9) inhibitor, in a poster presentation at the American Heart Association (AHA) Scientific Sessions in Chicago. In a study of mice with left ventricular hypertrophy (LVH) in a standard preclinical heart failure model, mice treated with CRD-733 were protected from LVH and showed improvement in several other markers of heart failure.

“These data provide strong evidence for the potential therapeutic benefit of PDE9 inhibition in a preclinical model of heart failure,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “Based on these data, and the established safety and tolerability of CRD-733 in humans, we are excited to announce initiation of the first clinical trial of CRD-733 in patients with heart failure.”

As a result of Cardurion Pharmaceuticals’ preclinical data, the recent successful Phase 1 study in normal subjects, and the safety and tolerability of CRD-733 in more than 250 subjects to date, the company has now initiated its Phase 1b study in heart failure. The randomized, double-blind study is evaluating CRD-733 in patients with heart failure in the U.S. and Europe. The trial will include 44 patients in each sub-population of heart failure, heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). Results are expected in 2019.

About CRD-733
CRD-733 is a Phosphodiesterase-9 enzyme (PDE-9) inhibitor. PDE-9 activity is abnormally elevated in heart failure which can impede activation of the heart’s normal responses to stress and make the heart more vulnerable to damage. In preclinical models of heart failure, inhibiting PDE-9 with CRD-733 restores these heart-protective mechanisms and has been shown to prevent and reverse heart muscle malfunction brought on by abnormal stress. Cardurion Pharmaceuticals obtained an exclusive, worldwide, royalty-bearing license from Astellas to research, develop, manufacture and commercialize CRD-733 for the diagnosis, prevention, and treatment of cardiovascular-related indications in humans.

About Heart Failure
Heart failure is marked by progressive weakening or stiffening of the heart muscle and the organ’s gradual loss of blood-pumping ability. Although symptoms can be managed, this is a chronic condition with no cure. With more than 26 million people with heart failure worldwide1 and 6.5 million people with heart failure in the United States2, heart failure is the most important remaining unmet need in cardiovascular disease. In the United States, heart failure accounts for more than 1 million hospital admissions2 and costs approximately $30 billion dollars each year to treat3. Not only are these costs expected to rise to almost $70 billion by 20303, the incidence of heart failure is projected to rise 46 percent – resulting in more than 8 million people with heart failure in the United States4. There are two forms of heart failure: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). HFrEF, formerly known as systolic heart failure, is characterized by a decrease in the ability of the heart to eject blood sufficiently during contraction. HFpEF is the form of heart failure that occurs when the left ventricle becomes stiff and though it continues to eject blood normally, in HFpEF the heart’s ability to relax is reduced, causing it to be unable to fill with blood sufficiently. The prognosis of patients with HFpEF is similar to that of HFrEF5. Roughly half of the patients with heart failure have HFpEF5, for which there are no approved therapies.

About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine, and drug development, Cardurion Pharmaceuticals’ unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion Pharmaceuticals has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Cardurion Pharmaceuticals’ Forward-Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Global Public Health Burden of Heart Failure. Cardiac Failure Review (2017)
American Heart Association, Causes and Risks for Heart Failure (February 2018)
Circ Heart Fail. 2013 May ; 6(3): 606–619. doi:10.1161/HHF.0b013e318291329a
American Heart Association, Heart Disease and Stroke Statistics (January 2017)
5 Owen et al (2006) N Engl J Med

Contacts

W2O pure
Anne Lucke, +1 646-698-8474
alucke@w2ogroup.com

Read More

Silvia Priori, M.D., Ph.D. Delivers the William Harvey Lecture on Basic Science

CAMBRIDGE, MASS. – [October 2, 2018] – The European Society of Cardiology Congress holds four specialized lectures each year and selects four renowned scientists who are seen by their peers as leading experts in their corresponding fields. The William Harvey Lecture on Basic Science is a noteworthy accolade and recognizes a member of the scientific community specializing in cardiology.

Silvia Priori, M.D., Ph.D. was selected to deliver the William Harvey Lecture on Basic Science this year. On August 26th, Dr. Priori spoke about her inherited arrhythmogenic diseases study and the significant developments it has made in understanding the genetic basis of these types of diseases. With these results, she hopes to provide a foundation for gene therapies to fix the consequences of the flawed genes and bring new treatments to the clinic.

“Receiving the Harvey Lecture Award is really a great feeling and arrived at a time in which the advancements in molecular medicine are reaching the clinics with the promise of a better future for our patients,” said Dr. Priori.

Dr. Priori is a professor of Cardiology in the Department of Molecular Medicine at the University of Pavia, scientific director and director of the Cardiology Division at the Istituti Clinici Scientifici Maugeri and a director of the Molecular Cardiology Laboratories at the Centro National de Investigaciones Cardiovasculares Carlos III. Dr. Priori has received numerous prestigious honors and awards from scientific societies around the world, including the Distinguished Scientist Award of the Heart Rhythm Society and the Outstanding Research in Pediatric Cardiology award of the American Heart Association. Dr. Priori joined the Cardurion Pharmaceuticals scientific advisory board in September 2018.

Read More

Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

CAMBRIDGE, MASS. – [September 20, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9 (PDE-9) inhibitor in development to improve cardiac function in heart failure patients. Recent evidence supports that inhibition of PDE-9 has the potential to restore heart-protective mechanisms that are dysfunctional in heart failure, as well as improve heart muscle function and size. A Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of CRD-733 in healthy volunteers was recently initiated.

“The advancement of CRD-733 into the clinic is an important milestone for Cardurion as we move our portfolio’s lead program forward toward treatment of heart failure, the most important unmet need in cardiovascular medicine,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “Compelling preclinical evidence supports that CRD-733 can enhance cardiac function in both known forms of heart failure. With limited options at present for those living with heart failure, we are excited about the potential for CRD-733 to have a positive impact on these patients.”

Cardurion Pharmaceuticals entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733 earlier this year.

About CRD-733

CRD-733 is a Phosphodiesterase-9 enzyme (PDE-9) inhibitor. PDE-9 activity is abnormally elevated in heart failure which can impede activation of the heart’s normal responses to stress and make the heart more vulnerable to damage. In preclinical models of heart failure, inhibiting PDE-9 with CRD-733 restores these heart-protective mechanisms and has been shown to prevent and reverse heart muscle malfunction brought on by abnormal stress. Cardurion Pharmaceuticals obtained an exclusive, worldwide, royalty-bearing license from Astellas to research, develop, manufacture and commercialize CRD-733 for the diagnosis, prevention, and treatment of cardiovascular-related indications in humans.

About Heart Failure

Heart failure is marked by progressive weakening or stiffening of the heart muscle and the organ’s gradual loss of blood-pumping ability. Although symptoms can be managed, this is a chronic condition with no cure. With more than 26 million people with heart failure worldwide1 and 6.5 million people with heart failure in the United States,2 heart failure is the most important remaining unmet need in cardiovascular disease. In the United States, heart failure accounts for more than 1 million hospital admissions2 and costs approximately $30 billion dollars each year to treat3. Not only are these costs expected to rise to almost $70 billion by 20303, the incidence of heart failure is projected to rise 46 percent – resulting in more than 8 million people with heart failure in the United States4.

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine, and drug development, Cardurion Pharmaceuticals’ unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion Pharmaceuticals has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Cardurion Pharmaceuticals’ Forward Looking Statements

This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Global Public Health Burden of Heart Failure. Cardiac Failure Review (2017)

American Heart Association, Causes and Risks for Heart Failure (February 2018)

Circ Heart Fail. 2013 May ; 6(3): 606–619. doi:10.1161/HHF.0b013e318291329a

American Heart Association, Heart Disease and Stroke Statistics (January 2017)

Media
Stephanie Hutton
W2O pure
shutton@w2ogroup.com
+1 910.726.1367

Read More

Cardurion Pharmaceuticals Appoints Jeb Keiper to Its Board of Directors

CAMBRIDGE, MASS. – [August 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr. Keiper joins founder Michael Mendelsohn, M.D., Ken Novack, Ed Mascioli, M.D. and chief executive officer Daniel Bloomfield, M.D. as members, along with board observers, Stephen Hitchcock, Ph.D. and Keith Gottesdiener, M.D.

“We are fortunate to have amassed a tremendous breadth and depth of expertise in drug discovery, development, and business amongst our board members, observers and advisors, which positions Cardurion well to deliver on our vision of becoming the world’s leading cardiovascular drug company,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “We are thrilled to have Jeb share his expertise and leadership skills as Cardurion takes on the challenges and opportunities of the company’s next critical phase of growth.”

Jeb Keiper has 20 years of experience in the pharmaceutical and biotech industries with extensive expertise in financing and business development transactions. Mr. Keiper currently serves as chief financial officer and chief business officer at Nimbus Therapeutics, LLC, where he has overseen over $700m of capital inflows via a variety of financing and partnering transactions since joining in 2014. Prior to joining Nimbus, Mr. Keiper was vice president of business development at GSK Oncology and spent a decade at GSK in various business development leadership roles. Mr. Keiper led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014. Earlier in his career, Mr. Keiper was a consultant at McKinsey and Company and worked in business development at TransForm Pharmaceuticals. Mr. Keiper began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT: one in Chemistry, two in Chemical Engineering, and an MBA from MIT Sloan.

“Cardurion has built an exceptional company focused on addressing multiple pathways in the cardiomyocyte,” said Mr. Keiper. “I look forward to working with the leadership team and fellow board members as Cardurion continues to build a novel portfolio of clinical and preclinical programs for patients with cardiovascular disease.”

For additional information on Cardurion Pharmaceuticals’ board and leadership team, please visit the company’s website: http://www.cardurion.com.

About Cardurion Pharmaceuticals

Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Cardurion Pharmaceuticals’ Forward Looking Statements

This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Read More

Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer

CAMBRIDGE, MASS. – [July 24, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.

“The expansion of our leadership team will not only allow us to streamline and optimize our operations, but further execute on our strategic vision to deliver breakthrough treatments to target major unmet needs in cardiovascular medicine,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “Cardiovascular disease is the leading cause of death in both men and women and accounts for one-third of deaths worldwide.1,2 Rebecca’s strategic know-how and operational ingenuity will be critical for Cardurion as we pursue our goal to transform the treatment of cardiovascular disease.”

Rebecca is a highly regarded leader who brings almost 20 years of strategic and operational biotech experience to Cardurion Pharmaceuticals. As chief operating officer, Rebecca will formulate strategies and lead all aspects of operations to maximize value creation. Prior to joining Cardurion Pharmaceuticals, Rebecca served as executive vice president of operations at Prevail Therapeutics, where she led clinical operations and early development planning. Prior to that, Rebecca spent eleven years at Alexion Pharmaceuticals. During her tenure, Rebecca held a wide range of leadership roles in development, project management and manufacturing, including vice president of operations and chief of staff to the CEO. Before Alexion, Rebecca spent six years in clinical operations and medical affairs at Novartis Pharmaceuticals. Rebecca earned her Doctor of Pharmacy from Northeastern University and completed her post-doctoral clinical research fellowship at Northeastern University and Tufts Medical Center. She is a 2017 graduate of the Women in Bio Boardroom Ready program.

“There exists a critical medical need for innovation to overcome the burden of cardiovascular diseases, and I’m pleased to join a world-class team of cardiologists with a deep understanding and desire to advance treatments for patients who are living with heart failure,” said Rebecca Frey, chief operating officer at Cardurion Pharmaceuticals. “I am excited to bring my capability and passion for disciplined execution to Cardurion’s management team, and I look forward to delivering on the company’s strategic priorities.”

For additional information on Cardurion Pharmaceuticals’ leadership team, please visit the company’s website: http://www.cardurion.com.

About Cardurion Pharmaceuticals
Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Cardurion Pharmaceuticals’ Forward Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

American Heart Association, Causes and Risks for Heart Failure (February 2018)
2 American College of Cardiology, Cardiovascular disease causes one-third of deaths worldwide (May 2017)

Media
Stephanie Hutton
W2O pure
shutton@w2ogroup.com
+1 910.726.1367

Read More

Cardurion Pharmaceuticals Announces Formation of Scientific and Clinical Advisory Board

CAMBRIDGE, MASS. – [June 26, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has assembled world-class Scientific and Clinical Advisory Boards.

“Cardiovascular disease is the leading cause of death in both men and women and accounts for one-third of deaths worldwide1,2,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “The insight and expertise of our scientific and clinical advisory board will be critical as we advance our pipeline of novel treatments to reduce the burden of this public health issue. We are honored and extremely fortunate to welcome such distinguished visionaries and clinicians to the team.”

Cardurion Pharmaceuticals is pleased to share the members of its Scientific and Clinical Advisory Boards.

Cardurion Pharmaceuticals Scientific Advisory Board

  • Eric Olson, Ph.D., scientific advisory board chairman, Cardurion Pharmaceuticals; professor and chairman, UT Southwestern Medical Center
  • Douglas Mann, M.D., chief of cardiology, Washington University School of Medicine
  • David Kass, M.D., professor of medicine and cardiology, John Hopkins University School of Medicine

“Cardurion is targeting key and well validated pathways to enhance heart function,” said Dr. Eric Olson, scientific advisory board chairman, Cardurion Pharmaceuticals.  “Cardurion has a tremendous team with deep expertise in developing pioneering therapies, and I look forward to working alongside these leaders to advance treatments for heart failure and other cardiovascular disorders.”

Cardurion Pharmaceuticals Clinical Advisory Board

  • James Udelson, M.D., clinical advisory board chairman, Cardurion Pharmaceuticals; chief of cardiology, Tufts Medical Center and professor of medicine and radiology, Tufts University School of Medicine
  • Eugene Braunwald, M.D., distinguished Hersey professor of medicine, Harvard Medical School; founding chairman, Thrombolysis in Myocardial Infraction Study Group
  • John McMurray M.D., professor of medical cardiology and deputy director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK
  • Scott Solomon, M.D., the Edward D. Frohlich distinguished chair, professor of medicine, Harvard Medical School; senior physician, Brigham and Women’s Hospital

“There remains a critical need for innovation to address the burden of several major cardiovascular diseases, including heart failure,” said Dr. Eugene Braunwald. “I am deeply impressed by Cardurion’s team and focus and believe this new company is well poised to make a real difference to patients.”

For additional information on Cardurion Pharmaceuticals’ Scientific and Clinical Advisory Boards, please visit the company’s website: http://www.cardurion.com.

About Cardurion Pharmaceuticals

Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Cardurion Pharmaceuticals’ Forward Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

American Heart Association, Causes and Risks for Heart Failure (February 2018)
2 American College of Cardiology, Cardiovascular disease causes one-third of deaths worldwide (May 2017)

 

Media
Stephanie Hutton
W2O pure
shutton@w2ogroup.com
+1 910.726.1367

Read More

Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas

Company expanding pipeline of novel treatments for cardiovascular disease

CAMBRIDGE, MASS. – [April 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients.

Under the terms of the agreement, Astellas has granted Cardurion Pharmaceuticals an exclusive, worldwide, royalty-bearing license, to research, develop, manufacture and commercialize CRD-733 for the diagnosis, prevention and treatment of cardiovascular-related indications in humans.

Heart failure is a chronic, progressive syndrome in which the heart is unable to adequately meet the body’s needs for blood and oxygen, resulting in shortness of breath, fatigue, and fluid retention. Heart failure can occur with either a weak heart muscle that cannot adequately eject blood, or a muscle that is strong enough, but other factors limiting its ability to fill or increase function, as needed, are impaired. Over 6 million people in the United States have one of these two forms of heart failure1, and this unmet medical need poses the greatest challenge in cardiovascular medicine today. Recent evidence supports that inhibition of PDE-9 has potential to restore heart-protective mechanisms that are dysfunctional in both forms of heart failure.

“Heart failure is an expanding global problem that remains one of the major unmet medical needs in cardiovascular disease,” said David Kass, M.D., scientific advisor at Cardurion Pharmaceuticals and professor of medicine at the Johns Hopkins University School of Medicine, who first discovered the key role of PDE-9 inhibition in heart failure. “PDE-9 is abnormally elevated in human failing hearts, which can impede a natural protective pathway and make the heart more vulnerable to damage. In our studies, inhibiting PDE-9 was able to prevent and reverse heart malfunction brought on by abnormal stress. Inhibiting PDE-9 in patients has the real potential to treat multiple forms of heart failure2.”

“Cardiovascular disease is the leading cause of death worldwide in both men and women, accounting for over 17 million deaths per year3,” said Daniel Bloomfield, chief executive officer of Cardurion Pharmaceuticals. “We are pleased to enter this agreement with Astellas to develop and commercialize CRD-733 and provide a new therapeutic option to heart failure patients. We look forward to advancing CRD-733 into further clinical development in 2018.”

 

About Cardurion Pharmaceuticals

Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

 

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas focuses on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. Astellas is also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

 

Cardurion’s Forward Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, including, but not limited to, statements that express or imply future outcomes of our partnership with Takeda, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

 

1 American Heart Association, Causes and Risks for Heart Failure (February 2018)

2 Lee, D. et al. Phosphodiesterase 9A controls nitric-oxideindependent cGMP and hypertrophic heart disease. Nature. 519, 472-476 (2015)

3 World Health Organization, Cardiovascular diseases (May 2017)

 

Media Contact for Cardurion
Stephanie Hutton
W2Opure
shutton@w2ogroup.com
+1 910.726.1367

Read More
page 1 of 2